Alexza Pharma (ALXA) Tops Q4 EPS by 33c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- U.S. EV market shows signs of bottoming out: Bernstein
Alexza Reports Fourth Quarter and Year End 2014 Financial Results
March 9, 2015 4:10 PM EDTMOUNTAIN VIEW, Calif., March 9, 2015 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter and year ended December 31, 2014. The net loss for the fourth quarter was $6.7 million compared to $5.7 million during the same quarter in 2013. The net loss for the years ended December 31, 2014 and 2013 was $36.7 million and $39.6 million, respectively.  At December 31, 2014, Alexza had consolidated cash, cash equivalents, marketable securities, and restricted cash of $37.5 million.
"During 2015 and beyond, we see several value opportunities for Alexza," said Thomas B. King, President and CEO of Alexza. "We believe... More
